Stylianos Michalakis Selected Research

Color Vision Defects (Color Blindness)

11/2022	Three-year results of phase I retinal gene therapy trial for CNGA3-mutated achromatopsia: results of a non randomised controlled trial.
4/2022	A Bioengineered In Vitro Model to Assess AAV-Based Gene Therapies for Cyclic GMP-Related Disorders.
1/2022	Achromatopsia: Genetics and Gene Therapy.
1/2021	Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders.
12/2020	The cGMP-Dependent Protein Kinase 2 Contributes to Cone Photoreceptor Degeneration in the Cnga3-Deficient Mouse Model of Achromatopsia.
12/2018	Accessory heterozygous mutations in cone photoreceptor CNGA3 exacerbate CNG channel-associated retinopathy.
1/2018	Design and Development of AAV-based Gene Supplementation Therapies for Achromatopsia and Retinitis Pigmentosa.
12/2017	AAV8 Can Induce Innate and Adaptive Immune Response in the Primate Eye.
1/2017	Endoplasmic reticulum (ER) Ca2+-channel activity contributes to ER stress and cone death in cyclic nucleotide-gated channel deficiency.
1/2017	AAV-Mediated Gene Supplementation Therapy in Achromatopsia Type 2: Preclinical Data on Therapeutic Time Window and Long-Term Effects.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stylianos Michalakis Research Topics

Disease

11	Color Vision Defects (Color Blindness) 11/2022 - 10/2013
11	Retinal Degeneration 01/2022 - 01/2005
9	Retinitis Pigmentosa (Pigmentary Retinopathy) 10/2021 - 03/2011
4	Blindness (Hysterical Blindness) 03/2021 - 01/2014
4	Channelopathies 03/2018 - 01/2009
3	Choroidal Neovascularization 08/2022 - 01/2021
3	Retinal Dystrophies 04/2022 - 01/2021
3	Eye Diseases (Eye Disease) 01/2019 - 03/2014
2	Infections 01/2022 - 12/2021
2	Achromatopsia 2 01/2022 - 01/2017
2	Retinal Diseases 02/2021 - 06/2017
2	Cone Dystrophy 12/2018 - 01/2010
2	Pain (Aches) 01/2017 - 08/2011
2	Cone-Rod Dystrophies 01/2016 - 03/2014
1	Neoplasms (Cancer) 08/2022
1	Achromatopsia 3 01/2022
1	Alzheimer Disease (Alzheimer's Disease) 01/2020
1	Disease Progression 01/2019
1	Hypoxia (Hypoxemia) 12/2018
1	Macular Degeneration (Age-Related Maculopathy) 12/2018
1	Ciliopathies 01/2018
1	Retinal Detachment (Retinal Detachments) 07/2015
1	Blister (Bulla) 07/2015
1	Parkinson Disease (Parkinson's Disease) 05/2014
1	3 X-Linked Cone-Rod Dystrophy 03/2014
1	congenital stationary Night blindness 03/2014
1	Hypersensitivity (Allergy) 08/2011
1	Inflammation (Inflammations) 08/2011
1	Ganglion Cysts (Ganglion) 06/2010
1	Gliosis 01/2005

Drug/Important Bio-Agent (IBA)

16	Retinaldehyde (Retinal)IBA 11/2022 - 01/2005
6	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2009
5	Cyclic NucleotidesIBA 12/2018 - 06/2010
3	Rhodopsin (Visual Purple)IBA 01/2020 - 11/2014
2	Peptides (Polypeptides)IBA 01/2022 - 01/2020
2	Cyclic Nucleotide-Gated Cation ChannelsIBA 10/2021 - 01/2005
2	CationsIBA 01/2021 - 12/2020
2	Guanosine Monophosphate (5' Guanylic Acid)IBA 12/2020 - 12/2010
2	OpsinsIBA 01/2020 - 01/2017
2	Type 6 Cyclic Nucleotide PhosphodiesterasesIBA 01/2019 - 12/2017
2	Ion Channels (Ion Channel)IBA 12/2018 - 06/2010
1	DepsipeptidesIBA 08/2022
1	vioprolide AIBA 08/2022
1	Nuclear Proteins (Protein, Nuclear)IBA 08/2022
1	Biological ProductsIBA 04/2022
1	Neutralizing AntibodiesIBA 01/2022
1	CalpainIBA 01/2022
1	Cyclic GMP-Dependent Protein Kinase Type IIIBA 12/2020
1	Amyloid beta-PeptidesIBA 01/2020
1	Amyloid (Amyloid Fibrils)IBA 01/2020
1	EnzymesIBA 01/2019
1	NucleosidesIBA 01/2019
1	Transcription Factors (Transcription Factor)IBA 12/2018
1	Biomarkers (Surrogate Marker)IBA 01/2018
1	pericentrinIBA 01/2018
1	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 12/2017
1	LigandsIBA 06/2017
1	azobenzeneIBA 06/2017
1	Hyperpolarization-Activated Cyclic Nucleotide-Gated ChannelsIBA 01/2017
1	SynucleinsIBA 05/2014
1	L-Type Calcium Channels (Dihydropyridine Receptor)IBA 03/2014
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 08/2011
1	ZymosanIBA 08/2011
1	Green Fluorescent ProteinsIBA 01/2010

Therapy/Procedure

8	Therapeutics 04/2022 - 10/2013
4	Lasers (Laser) 08/2022 - 01/2010
1	Light Coagulation 08/2022
1	Critical Care (Surgical Intensive Care) 12/2021
1	Aftercare (After-Treatment) 01/2020
1	Intraocular Injections 01/2019